• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Terns Pharmaceuticals Inc.

    3/20/25 4:36:40 PM ET
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TERN alert in real time by email
    S-8 1 tern-s8-q125.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 20, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

    Terns Pharmaceuticals, Inc.

    (Exact name of Registrant as specified in its charter)

    Delaware

     

    98-1448275

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification Number)

     

     

    1065 East Hillsdale Blvd., Suite 100
    Foster City, California

     

     

    94404

    (Address of Principal Executive Offices)

     

    (Zip Code)

    2021 Incentive Award Plan

    2021 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Amy Burroughs, M.B.A.

    Chief Executive Officer

    Terns Pharmaceuticals, Inc.

    1065 East Hillsdale Blvd., Suite 100

    Foster City, California 94404

    (650) 525-5535

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

     

    Brian A. Johnson

    Wilmer Cutler Pickering Hale and Dorr LLP

    7 World Trade Center

    250 Greenwich Street

    New York, New York 10007

    Telephone: (212) 230-8800

     

    Copies to:

     

    Elona Kogan, Esq.

    Chief Legal Officer

    Terns Pharmaceuticals, Inc.

    1065 East Hillsdale Blvd., Suite 100

    Foster City, California 94404

    (650) 525-5535

     

     

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    Proposed sale to take place as soon after the effective date of the
    registration statement as awards under the plans are exercised and/or vest.

     

     

     


     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 5,227,594 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Forms S-8 (File No. 333-253085, 333-263340 and 333-271944) are effective: (i) the 2021 Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 4,356,329 shares of common stock, and (ii) the 2021 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 871,265 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON
    FORM S-8

    Pursuant to Instruction E of Form S-8, the contents of (i) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on February 12, 2021 (File No. 333-253085), (ii) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 7, 2022 (File No. 333-263340), (iii) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 15, 2023 (File No. 333-271944) and (iv) the Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 14, 2024 (File No. 333-277943) are incorporated by reference herein.

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the SEC.

    Item 8. Exhibits

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit Number

     

    Exhibit Description

     

    Form

     

    Date

     

    Number

     

    Filed Herewith

    4.1

     

    Amended and Restated Certificate of Incorporation.

     

    8-K

     

    2/9/2021

     

    3.1

     

     

    4.2

     

    Amended and Restated Bylaws.

     

    8-K

     

    10/10/2023

     

    3.1

     

     

    4.3

     

    Form of Common Stock Certificate.

     

    S-1/A

     

    2/1/2021

     

    4.2

     

     

    5.1

     

    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP.

     

     

     

     

     

     

     

    X

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

    X

    23.2

     

    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

    X

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

    X

    99.1(a)#

     

    2021 Incentive Award Plan.

     

    S-8

     

    2/12/2021

     

    99.2(a)

     

     

    99.1(b)#

     

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(b)

     

     

    99.1(c)#

     

    Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(c)

     

     

    99.1(d)#

     

    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.

     

    S-1/A

     

    2/1/2021

     

    10.5(d)

     

     

    99.2#

     

    2021 Employee Stock Purchase Plan.

     

    S-8

     

    2/12/2021

     

    99.3

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

    X

     

    # Indicates management contract or compensatory plan.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on this 20th day of March, 2025.

     

    Terns Pharmaceuticals, Inc.

    By:

    /s/ Amy Burroughs

    Amy Burroughs, M.B.A.

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Amy Burroughs and Andrew Gengos, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.

    Signature

    Title

    Date

    /s/ Amy Burroughs

    Chief Executive Officer and Director

    (Principal Executive Officer)

    March 20, 2025

    Amy Burroughs, M.B.A.

     

    /s/ Andrew Gengos

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

    March 20, 2025

    Andrew Gengos, M.B.A.

    /s/ David Fellows

    Chairman of the Board of Directors

    March 20, 2025

    David Fellows

    /s/ Robert Azelby

    Director

    March 20, 2025

    Robert Azelby

    /s/ Jeffrey Kindler

    Director

    March 20, 2025

    Jeffrey Kindler, Esq.

    /s/ Hongbo Lu

    Director

    March 20, 2025

    Hongbo Lu, Ph.D.

    /s/ Jill Quigley

    Director

    March 20, 2025

    Jill Quigley, Esq.

    /s/ Radhika Tripuraneni

    Director

    March 20, 2025

    Radhika Tripuraneni, M.D.

    /s/ Heather Turner

    Director

    March 20, 2025

    Heather Turner, J.D.

     

     

     


    Get the next $TERN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TERN

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    10/31/2024$82.00Outperform
    Oppenheimer
    6/22/2023$16.00Buy
    Mizuho
    6/7/2023$18.00Buy
    Jefferies
    5/31/2023$23.00Buy
    ROTH MKM
    5/8/2023$18.00Outperform
    BMO Capital Markets
    2/14/2023$17.00Mkt Outperform
    JMP Securities
    2/7/2023$19.00Buy
    UBS
    More analyst ratings

    $TERN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Terns Pharmaceuticals

      William Blair initiated coverage of Terns Pharmaceuticals with a rating of Mkt Perform

      2/28/25 7:33:47 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Terns Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Terns Pharmaceuticals with a rating of Outperform and set a new price target of $82.00

      10/31/24 6:27:13 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Terns Pharmaceuticals with a new price target

      Mizuho initiated coverage of Terns Pharmaceuticals with a rating of Buy and set a new price target of $16.00

      6/22/23 7:23:07 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2025, and provided corporate updates. "Terns had a strong start to

      5/8/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

      FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with T

      5/2/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference

      FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET. A live webcast of the fireside chat will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns' website for at least 30 days

      4/30/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Financials

    Live finance-specific insights

    See more
    • Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

      Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo adjusted) Well-tolerated with no treatment-related dose interruptions, reductions, or discontinuations even with rapid dose titration Distinct drug properties support potential to be a leading GLP-1R agonist Plans to initiate Phase 2 clinical trial in 2025 Company to host conference call today at 8:00 am ET FOSTER CITY, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, today announced positive top-line data from

      9/9/24 7:05:00 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

      TERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidate

      8/8/23 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/15/24 10:35:07 AM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/14/24 7:00:26 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Terns Pharmaceuticals Inc.

      SC 13G/A - Terns Pharmaceuticals, Inc. (0001831363) (Subject)

      11/14/24 5:51:38 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Business Officer Jung Melita Sun bought $11,498 worth of shares (2,250 units at $5.11) (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/3/25 7:28:43 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Burroughs Amy L. bought $2,606 worth of shares (510 units at $5.11), increasing direct ownership by 3% to 19,609 units (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/3/25 7:25:48 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Burroughs Amy L. bought $110,468 worth of shares (15,450 units at $7.15), increasing direct ownership by 423% to 19,099 units (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      12/9/24 6:04:56 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Leadership Updates

    Live Leadership Updates

    See more
    • Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

      FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transfor

      2/24/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

      FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service. "I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operationa

      2/20/25 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

      FOSTER CITY, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service. "It is my pleasure to welcome Heather to the Terns Board, and I am confide

      11/18/24 4:05:00 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Kuriakose Emil sold $2,366 worth of shares (952 units at $2.49), decreasing direct ownership by 2% to 53,317 units (SEC Form 4)

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      4/2/25 6:48:56 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Gengos Andrew

      4 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/25/25 6:12:34 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Gengos Andrew

      3 - Terns Pharmaceuticals, Inc. (0001831363) (Issuer)

      2/25/25 6:10:09 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TERN
    SEC Filings

    See more
    • SEC Form S-3 filed by Terns Pharmaceuticals Inc.

      S-3 - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

      5/8/25 4:42:52 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Terns Pharmaceuticals Inc.

      10-Q - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

      5/8/25 4:15:55 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Terns Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Terns Pharmaceuticals, Inc. (0001831363) (Filer)

      5/8/25 4:10:14 PM ET
      $TERN
      Biotechnology: Pharmaceutical Preparations
      Health Care